• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MediWound Ltd. - Ordinary Shares (NQ:MDWD)

    14.38 +0.17 (+1.20%)
    Streaming Delayed Price Updated: 1:54 PM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MediWound Ltd. - Ordinary Shares

    < Previous 1 2 3 4 Next >
    News headline image
    MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report First Quarter 2026 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Files Annual Report on Form 20-F
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Present at Upcoming Investor Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report Third Quarter 2025 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report Second Quarter 2025 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
    Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report First Quarter 2025 Financial Results
    Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
    Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time 
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound to Present at the 45th Annual TD Cowen Health Care Conference
    From MediWound Ltd.
    Via GlobeNewswire
    News headline image
    MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
    From MediWound Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.